Shell Stocks; Reverse Mergers; Acquisitions; Zombies; Greys; & All "Other" Plays

[$hellKing]

TR_GM 8k out couple days ago. CEO resigned and another officer took over. Website still up. Could be a comeback type

http://www.tmedpharma.com

Has a decent commercialized pipeline:

Pipeline:

Targeted Medical Pharma is focused on product development in areas with the greatest medical and commercial promise. We are committed to developing medications for diseases where the current treatment modalities are ineffective or associated with adverse side effects. Our current pipeline is focused on addressing chronic pain and inflammation, asthma, anemia, autism, obesity, diabetes, posttraumatic stress disorder and other diseases of the nervous system.

Therapeutic Area Product Name Product Class Commercialization
Pain and inflammation (chronic) Theramine® Medical Food Complete
Pain and inflammation (arthritis) Trepadone® Medical Food Complete
Pain and inflammation (neuropathy) Percura® Medical Food Complete
Sleep disorders associated with depression, PTSD, fibromyalgia Sentra PM® Medical Food Complete
Sleep disorders associated with anxiety GABAdone® Medical Food Complete
Chronic fatigue, pain, cognitive disorders Sentra AM® Medical Food Complete
Obesity AppTrim® Medical Food Complete
Hypertension Hypertensa® Medical Food Complete
Viral infection, impaired immunity Lister V® Medical Food Complete
Nasal Congestion/Snoring ClearWayz™ Dietary Supplement Complete
Autism, autism spectrum disorders Auspect™ Medical Food TBD
Asthma Pulmona New Medical Food TBD

8k Yesterday


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 6, 2017, Mr. Kim Giffoni tendered his resignation as Interim Chief Executive Officer of Targeted Medical Pharma, Inc. (the “Company” ) to focus on other business activities. At the time of his resignation, Mr. Giffoni served as Interim Chief Executive Officer and Director. Mr. Giffoni will remain a member of the Company’s Board and will serve as the Company’s Executive Vice President of Foreign Sales. Mr. Giffoni did not resign as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company ¨If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

An interim Chief Executive Officer, Marcus Charuvastra, the Company’s former VP of Operations and Marketing and a current Director has been appointed by the board.

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 12, 2017

TARGETED MEDICAL PHARMA, INC.


By: /s/ Marcus Charuvastra
Name: Marcus Charuvastra
Interim Chief Executive Officer